Oviva Therapeutics, a biotech startup focused on preventing ovarian aging, has scored $11.5 million in seed funding from Cambrian Biopharma, CEO Daisy Robinton tells Axios exclusively.
Why it matters: Ovaries aren't only about reproduction. They are the first organ to decline with age, and as they do, accelerate and give rise to many other women's health problems.
